Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Clin J Am Soc Nephrol. 2022 May;17(5):684-692. doi: 10.2215/CJN.14701121. Epub 2022 Apr 26.
The risk variants (G1 and G2) are associated with kidney disease among Black adults, but the clinical presentation is heterogeneous. In mouse models and cell systems, increased gene expression of G1 and G2 confers cytotoxicity. How risk variants relate to the circulating proteome warrants further investigation.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 461 African American Study of Kidney Disease and Hypertension (AASK) participants (mean age: 54 years; 41% women; mean GFR: 46 ml/min per 1.73 m), we evaluated associations of risk variants with 6790 serum proteins (measured SOMAscan) using linear regression models. Covariates included age, sex, percentage of European ancestry, and protein principal components 1-5. Associated proteins were then evaluated as mediators of -associated risk for kidney failure. Findings were replicated among 875 Atherosclerosis Risk in Communities (ARIC) study Black participants (mean age: 75 years; 66% women; mean eGFR: 67 ml/min per 1.73 m).
In the AASK study, having two (versus zero or one) risk alleles was associated with lower serum levels of APOL1 (=3.11E-13; =3.12E-06 [two aptamers]), APOL2 (1.45E-10), CLSTN2 (=2.66E-06), MMP-2 (=2.96E-06), SPOCK2 (=2.57E-05), and TIMP-2 (=2.98E-05) proteins. In the ARIC study, risk alleles were associated with APOL1 (=1.28E-11); MMP-2 (=0.004) and TIMP-2 (=0.007) were associated only in an additive model, and APOL2 was not available. high-risk status was associated with a 1.6-fold greater risk of kidney failure in the AASK study; none of the identified proteins mediated this association. APOL1 protein levels were not associated with kidney failure in either cohort.
risk variants were strongly associated with lower circulating levels of APOL1 and other proteins, but none mediated the -associated risk for kidney failure. APOL1 protein level was also not associated with kidney failure.
风险变异(G1 和 G2)与黑人群体的肾脏疾病有关,但临床表现存在异质性。在小鼠模型和细胞系统中,G1 和 G2 的基因表达增加会导致细胞毒性。风险变异与循环蛋白质组的关系需要进一步研究。
设计、设置、参与者和测量:在 461 名非裔美国肾脏病和高血压研究(AASK)参与者(平均年龄:54 岁;41%为女性;平均肾小球滤过率:46ml/min/1.73m)中,我们使用线性回归模型评估了风险变异与 6790 种血清蛋白(通过 SOMAscan 测量)之间的关联。协变量包括年龄、性别、欧洲血统百分比和蛋白质主成分 1-5。然后评估相关蛋白作为 -相关肾脏衰竭风险的中介。在 875 名社区动脉粥样硬化风险研究(ARIC)黑人参与者(平均年龄:75 岁;66%为女性;平均 eGFR:67ml/min/1.73m)中复制了发现结果。
在 AASK 研究中,与零或一个风险等位基因相比,携带两个(风险)等位基因与较低的血清 APOL1 水平相关(=3.11E-13;=3.12E-06[两个适体]),APOL2(1.45E-10),CLSTN2(=2.66E-06),MMP-2(=2.96E-06),SPOCK2(=2.57E-05)和 TIMP-2(=2.98E-05)蛋白。在 ARIC 研究中,风险等位基因与 APOL1 相关(=1.28E-11);MMP-2(=0.004)和 TIMP-2(=0.007)仅在加性模型中相关,而 APOL2 不可用。AASK 研究中,高危状态与肾脏衰竭的风险增加 1.6 倍相关;鉴定出的蛋白质均未介导这种关联。APOL1 蛋白水平与两个队列的肾脏衰竭均无关。
风险变异与 APOL1 和其他蛋白质的循环水平降低密切相关,但没有一种蛋白质可以介导与风险相关的肾脏衰竭风险。APOL1 蛋白水平也与肾脏衰竭无关。